Yixue Wen

Mianyang, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 12 publications

Ursodeoxycholic acid for the prevention of severe radiation dermatitis: a single-arm phase I/II trial protocol in patients with breast cancer undergoing postoperative radiotherapy in China.

Ursodeoxycholic acid for the prevention of severe radiation dermatitis: a single-arm phase I/II trial protocol in patients with breast cancer undergoing postoperative radiotherapy in China.

Journal: BMJ open

Published: October 21, 2025

FLASH-RT for pulmonary protection: a comprehensive review of mechanisms, technological advances, and clinical translation.

FLASH-RT for pulmonary protection: a comprehensive review of mechanisms, technological advances, and clinical translation.

Journal: Frontiers in oncology

Published: June 07, 2025

Sleep traits and breast cancer risk: a two-sample Mendelian randomization study.

Sleep traits and breast cancer risk: a two-sample Mendelian randomization study.

Journal: Scientific reports

Published: March 11, 2024

Efficacy and Safety of Dual Anti-HER2 Blockade and Docetaxel With or Without Carboplatin as Neoadjuvant Regimen for Treatment of HER2-Positive Breast Cancer.

Efficacy and Safety of Dual Anti-HER2 Blockade and Docetaxel With or Without Carboplatin as Neoadjuvant Regimen for Treatment of HER2-Positive Breast Cancer.

Journal: Technology in cancer research & treatment

Published: November 30, 2023

Prognostic Factors and Models for Elderly (≥70 Years Old) Primary Operable Triple-Negative Breast Cancer: Analysis From the National Cancer Database.

Prognostic Factors and Models for Elderly (≥70 Years Old) Primary Operable Triple-Negative Breast Cancer: Analysis From the National Cancer Database.

Journal: Frontiers in endocrinology

Published: January 17, 2022

Anlotinib Combined with S-1 in Third- or Later-Line Stage IV Non-Small Cell Lung Cancer Treatment: A Phase II Clinical Trial.

Anlotinib Combined with S-1 in Third- or Later-Line Stage IV Non-Small Cell Lung Cancer Treatment: A Phase II Clinical Trial.

Journal: The oncologist

Published: May 07, 2021

Single-Agent Versus Double-Agent Chemotherapy in Concurrent Chemoradiotherapy for Esophageal Squamous Cell Carcinoma: Prospective, Randomized, Multicenter Phase II Clinical Trial.

Single-Agent Versus Double-Agent Chemotherapy in Concurrent Chemoradiotherapy for Esophageal Squamous Cell Carcinoma: Prospective, Randomized, Multicenter Phase II Clinical Trial.

Journal: The oncologist

Published: May 06, 2020

Radical radiotherapy for metachronous oligometastasis after initial treatment of esophageal cancer.

Radical radiotherapy for metachronous oligometastasis after initial treatment of esophageal cancer.

Journal: Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology

Published: April 28, 2020

Anlotinib Combined with S-1 in the Third-Line Treatment of Stage IV Non-Small Cell Lung Cancer: Study Protocol for Phase II Clinical Trial.

Anlotinib Combined with S-1 in the Third-Line Treatment of Stage IV Non-Small Cell Lung Cancer: Study Protocol for Phase II Clinical Trial.

Journal: Asian Pacific journal of cancer prevention : APJCP

Published: September 20, 2019

Safety and efficacy of pulsed low-dose rate radiotherapy for local recurrent esophageal squamous cell carcinoma after radiotherapy: Study protocol for a prospective multi-center phase II trial.

Safety and efficacy of pulsed low-dose rate radiotherapy for local recurrent esophageal squamous cell carcinoma after radiotherapy: Study protocol for a prospective multi-center phase II trial.

Journal: Medicine

Published: July 03, 2019

S-1 versus S-1 plus cisplatin concurrent intensity modulated radiation therapy in the treatment of esophageal squamous cell carcinoma: Study protocol for a randomized controlled phase II trial.

S-1 versus S-1 plus cisplatin concurrent intensity modulated radiation therapy in the treatment of esophageal squamous cell carcinoma: Study protocol for a randomized controlled phase II trial.

Journal: Medicine

Published: December 17, 2017

Comparison of the clinical efficacy between single-agent and dual-agent concurrent chemoradiotherapy in the treatment of unresectable esophageal squamous cell carcinoma: a multicenter retrospective analysis.

Comparison of the clinical efficacy between single-agent and dual-agent concurrent chemoradiotherapy in the treatment of unresectable esophageal squamous cell carcinoma: a multicenter retrospective analysis.

Journal: Radiation oncology (London, England)

Published: August 03, 2017

Showing 1-12 of 12

Last Updated: 09/26/2026